SCHEMBL15054822

SCHEMBL15054822

CCC(=O)NS(=O)(=O)c1cccc(N)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.51
PRSS1 P07477 3/20 0.51
PRSS2 P07478 3/20 0.51
PRSS3 P35030 3/20 0.51
CYP19A1 P11511 1/20 0.51
PRMT1 Q99873 1/20 0.51
ALDH1A1 P00352 2/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
POLB P06746 1/20 0.50
CA2 P00918 2/20 0.49
LMNA P02545 1/20 0.49
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA4 P22748 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
FBP1 P09467 4/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6297904 0.82 TSHR (0.64) F2PRSS1PRSS2PRSS3CYP19A1
SCHEMBL19630979 0.81 FBP1 (0.62) FBP1HTR6
SCHEMBL15271107 0.81 EGFR (0.59) KAT6A
SCHEMBL15650208 0.80 ALDH1A1 (0.69) ALDH1A1TSHRTDP1CA2LMNA
SCHEMBL5050574 0.80 F2 (0.61) F2PRSS1PRSS2PRSS3CYP19A1
SCHEMBL13954376 0.80 LARS1 (0.60) KAT6A
SCHEMBL386093 0.80 KDM4E (0.57) CA2CA1
SCHEMBL7426443 0.80 F2 (0.50) F2PRSS1PRSS2PRSS3CYP19A1
SCHEMBL8549266 0.78 F2 (0.51) F2PRSS1PRSS2PRSS3CYP19A1
SCHEMBL8589883 0.78 ALDH1A1 (0.67) F2PRSS1PRSS2PRSS3CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2013096153-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK F2 3531/4885PRSS1 2502/4885PRSS2 3302/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK F2 2541/4885PRSS1 2542/4885PRSS2 3758/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK F2 3531/4885PRSS1 2502/4885PRSS2 3302/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK F2 3477/4885PRSS1 2387/4885PRSS2 3275/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK F2 3477/4885PRSS1 2387/4885PRSS2 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.